Leveraging PARP-1/2 to Target Distant Metastasis
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25169032 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mallory I Frederick und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Université de Montréal, Montreal, QC H3C 3T5, Canada. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Neoplasm Metastasis, Poly (ADP-Ribose) Polymerase-1, Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scotiabank Chair in the diagnosis and treatment of breast cancer, Institut de Cancer de Montréal, Centre de Recherche de Centre hospitalier de l'Université de Montréal.
Abstract (Originalsprache)
Poly (ADP-Ribose) Polymerase (PARP) inhibitors have changed the outcomes and therapeutic strategy for several cancer types. As a targeted therapeutic mainly for patients with BRCA1/2 mutations, PARP inhibitors have commonly been exploited for their capacity to prevent DNA repair. In this review, we discuss the multifaceted roles of PARP-1 and PARP-2 beyond DNA repair, including the impact of PARP-1 on chemokine signalling, immune modulation, and transcriptional regulation of gene expression, particularly in the contexts of angiogenesis and epithelial-to-mesenchymal transition (EMT). We evaluate the pre-clinical role of PARP inhibitors, either as single-agent or combination therapies, to block the metastatic process. Efficacy of PARP inhibitors was demonstrated via DNA repair-dependent and independent mechanisms, including DNA damage, cell migration, invasion, initial colonization at the metastatic site, osteoclastogenesis, and micrometastasis formation. Finally, we summarize the recent clinical advancements of PARP inhibitors in the prevention and progression of distant metastases, with a particular focus on specific metastatic sites and PARP-1 selective inhibitors. Overall, PARP inhibitors have demonstrated great potential in inhibiting the metastatic process, pointing the way for greater use in early cancer settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Université de Montréal, Montreal, QC H3C 3T5, Canada.
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), l'Institut de Cancer de Montreal, Montreal, QC H2X 0A9, Canada.
- Division of Surgical Oncology, Department of Surgery, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 0C1, Canada.
ORCID-Profile: Anna Clouvel, Saima Hassan
Förderung
- Scotiabank Chair in the diagnosis and treatment of breast cancer
- Institut de Cancer de Montréal
- Centre de Recherche de Centre hospitalier de l'Université de Montréal
- Centre de Recherche du Centre hospitalier de l’Université de Montréal (CRCHUM)
Zitieren
APA
Frederick, M. I., Abdesselam, D., Clouvel, A., Croteau, L., & Hassan, S. (2024). Leveraging PARP-1/2 to Target Distant Metastasis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25169032
Vancouver
Frederick MI, Abdesselam D, Clouvel A, Croteau L, Hassan S. Leveraging PARP-1/2 to Target Distant Metastasis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25169032
BibTeX
@article{Frederick2024,
author = {Frederick, Mallory I and Abdesselam, Djihane and Clouvel, Anna and Croteau, Laurent and Hassan, Saima},
title = {Leveraging PARP-1/2 to Target Distant Metastasis},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25169032}
}
EUVIMED